Core Insights - The company reported a revenue of approximately $101 million for the first half of 2025, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a significant year-on-year growth of 5,125% [1] - Earnings per share stood at $0.09 [1] Revenue Breakdown - Revenue from licensing fees increased from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing of innovative products [1] - Revenue from research services and technology licensing fees rose by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - In March 2025, the company entered into a global strategic partnership with AstraZeneca to co-develop next-generation multispecific antibodies targeting immune diseases, tumors, and other conditions [1] - The strategic partnership includes the use of the company's proprietary fully human antibody technology platform, Harbour Mice, for multiple projects across various therapeutic areas [1] - As part of this collaboration, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]
和铂医药-B公布中期业绩 实现收入约1.01亿美元 同比增长约3.27倍